CRISPR/Cas9 Guide RNA Design for C5 Gene Knockout
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for therapeutics that target the C5 gene to prevent and treat C5-associated diseases, as current treatments are inadequate in addressing the inflammatory and immune-related disorders linked to complement component 5.
Innovation Solution
The development of compositions comprising guide RNA or DNA encoding guide RNA, which targets the C5 gene using the CRISPR/Cas system to modify or reduce the expression of the C5 gene, thereby reducing the activity of complement C5 protein, utilizing lipid nanoparticles or viral vectors for delivery, and potentially combining with antigen-binding proteins to specifically target C5.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CRISPR/Cas system is used to target and edit the C5 gene, then the expression and activity of C5 protein is significantly reduced, but the complexity of the therapeutic composition and delivery system increases
Solution Approach 1:
The CRISPR/Cas9 system is divided into separate functional components: guide RNA (gRNA) for target recognition and Cas9 protein for cleavage activity. This segmentation allows independent optimization and delivery of each component, reducing overall system complexity while maintaining high editing efficiency.
Solution Approach 2:
Lipid nanoparticles serve as intermediary delivery vehicles that encapsulate and protect the CRISPR components during transport. These nanoparticles facilitate cellular uptake and intracellular release of gRNA and Cas9, simplifying the delivery process while ensuring efficient gene editing.
2Manufacturing precision
If guide RNA is designed to target specific exons of the C5 gene, then the specificity of C5 gene modification is improved, but the difficulty of detecting and measuring the target sequence increases
Solution Approach 1:
Guide RNAs are designed with specific sequences complementary to predetermined target sites in C5 gene exons (such as exon 1, 12, 15, 21, 22, or 27). This preliminary design ensures high specificity for the intended target sequence, enabling precise gene modification while facilitating detection through sequence-specific assays.
Solution Approach 2:
Traditional mechanical or chemical methods for achieving gene specificity are replaced with molecular recognition based on complementary base pairing between guide RNA and target DNA. This biological recognition system provides high specificity and simplifies detection through sequence-matching assays.
3Productivity
If lipid nanoparticles are used for delivering CRISPR components, then the delivery efficiency to cells is improved, but the manufacturing complexity of the therapeutic composition increases
Solution Approach 1:
The physical and chemical parameters of lipid nanoparticles are optimized for maximal delivery efficiency, including lipid composition, particle size, and surface charge. These parameter optimizations enhance cellular uptake and intracellular release of CRISPR components while establishing standardized manufacturing protocols.
Solution Approach 2:
The lipid nanoparticle formulation is designed as a universal delivery platform that can accommodate various CRISPR components (gRNA, Cas9 protein, or Cas9 mRNA) and potentially other therapeutic agents. This multi-functionality simplifies manufacturing by using a single delivery vehicle for different therapeutic payloads.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves significant reduction in C5 protein levels and activity, effectively inhibiting classical pathway hemolysis and providing therapeutic benefits for various C5-associated diseases by editing the C5 gene in cells, both in vitro and in vivo, with high editing efficiency and specificity.
Implementation Method 1
the guide RNA binds to a Cas protein and targets the Cas protein to the guide RNA target sequence in the C5 gene
Data Source
AI summary
Guide RNAs and CRISPR/Cas systems targeting a C5 locus or gene, lipid nanoparticles or viral vectors comprising such guide RNAs or CRISPR/Cas systems, and cells or animals comprising such guide RNAs or systems are provided. Methods of modifying or knocking down or knocking out a C5 locus or gene using the CRISPR/Cas systems are also provided, as well as use of the CRISPR/Cas systems in prophylactic and therapeutic applications for treatment and/or prevention of a disease, disorder, or condition associated with C5 and/or for ameliorating at least one symptom associated with such disease, disorder, or condition.